Phase 2 Kidney Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with a specific type of kidney cancer called clear cell renal cell carcinoma (ccRCC), confirmed by a tissue biopsy. A type of aggressive cancer cell pattern called sarcomatoid features is also allowed.
• People who are 18 years of age or older.
• People whose cancer has continued to grow or spread during or after at least one prior treatment for advanced (metastatic) kidney cancer, and whose prior treatment included both an immunotherapy drug (targeting PD-1 or PD-L1, with or without ipilimumab) and a targeted therapy drug that blocks blood vessel growth (a VEGFR-TKI).
• People whose cancer shows up as PSMA-positive on a special scan, meaning at least one tumour lesion shows higher activity than the liver on this scan, with no qualifying lesions showing low or no PSMA activity (confirm with trial site).
• People who have measurable tumour lesions that can be tracked over time using standard imaging criteria.
• People whose blood test results meet specific thresholds for white blood cells, red blood cells, platelets, kidney function, and liver function (the trial site will assess these results).
• People who are in good enough general health to carry out daily activities with little or no limitation, based on a standard medical scoring system (ECOG performance status of 0 or 1).
• Women who could become pregnant must have a negative pregnancy test within 72 hours before joining the trial.
• People who are able to use highly effective contraception during treatment and for at least 14 weeks after the last dose. Accepted methods include combined hormonal contraception (pill, patch, or vaginal ring), progestogen-only hormonal contraception (pill, injection, or implant), an intrauterine device (IUD), an intrauterine hormone-releasing system (IUS), surgical tubal occlusion, a vasectomised partner, or abstinence from sex.
• Women who are breastfeeding must stop breastfeeding before starting treatment and for 3 months after the last dose.
• People who are willing and able to give written informed consent, including agreeing to follow radiation safety precautions as recommended by the trial.

Who may not be able to join:

• People who have kidney cancer in only one kidney.
• People whose scans show any tumour lesions — in lymph nodes, solid organs, or bones — that do not show PSMA activity above the liver background level, and that meet certain size thresholds (confirm exact size criteria with trial site).
• People who have another cancer that could interfere with the trial treatment or results, such as prostate cancer.
• People who have active, uncontrolled, or symptomatic cancer spread to the brain or spinal cord. (People who have already been treated for brain or spinal involvement and whose disease is now stable and symptom-free may still be considered.)
• People whose personal, family, social, or geographical circumstances may make it difficult to follow the trial schedule and requirements.
• People with a known allergy or medical reason preventing them from receiving the imaging tracer or contrast dye used in the trial scans.

Important: Always verify eligibility with the trial site directly before applying.